SCHEMBL6793525

SCHEMBL6793525

CS(=O)(=O)NC(=O)COc1ccc(-c2ccccc2C(=O)Nc2ccc(NCCc3ccccn3)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
GAA P10253 2/20 0.43
POLB P06746 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
MAPT P10636 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SMO Q99835 2/20 0.41
LMNA P02545 3/20 0.40
HTT P42858 1/20 0.40
KDM4E B2RXH2 3/20 0.40
TDP1 Q9NUW8 1/20 0.39
PKM P14618 2/20 0.39
MITF O75030 1/20 0.39
JAK2 O60674 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793672 0.90 PKM (0.45) RAB9ANPC1SMN1; SMN2GAAPOLB
SCHEMBL6794937 0.90 NPC1 (0.48) RAB9ANPC1SMN1; SMN2GAAPOLB
SCHEMBL6789216 0.89 SMN1; SMN2 (0.48) RAB9ANPC1SMN1; SMN2GAAPOLB
SCHEMBL6787129 0.87 CA12 (0.51) RAB9ANPC1GAAPOLBCA12
SCHEMBL6792821 0.87 GAA (0.48) RAB9ANPC1SMN1; SMN2GAAPOLB
SCHEMBL6792973 0.86 NPC1 (0.47) RAB9ANPC1SMN1; SMN2GAAPOLB
SCHEMBL6794062 0.86 MEN1 (0.50) RAB9ANPC1GAAMAPTMEN1
SCHEMBL6795010 0.86 RAB9A (0.55) RAB9ANPC1SMN1; SMN2GAAPOLB
SCHEMBL6793336 0.85 RAB9A (0.65) RAB9ANPC1SMN1; SMN2GAAPOLB
SCHEMBL6796259 0.85 NPC1 (0.50) RAB9ANPC1SMN1; SMN2GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 RAB9A 3707/4885NPC1 64/4885SMN1; SMN2 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.